HEMAP samples ALL AML TCGA  showRefMap hideRefMap User guide

See Annotations Info

Annotation Info
The annotations have been obtained from GEO and reference articles for the samples. Annotations have been manually curated. Acute leukemias were sorted to precursor-B-cell- and precursor-T-cell acute lymphoblastic leukemias (ALL), and acute myeloid leukemias (AML). We used the FAB M0-M7 subtyping for AML. Chronic myelogenous leukemia (CML), juvenile myelomonocytic chronic leukemia (JMML), hairy cell leukemia (HCL) and chronic lymphoblastic leukemia (CLL) are also represented in the dataset. In addition, the retrieved dataset covers 9 B-cell lymphoma types (Burkitt?s lymphoma (BL), classical Hodgkin?s lymphoma (CHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue lymphoma (MALT), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), nodular lymphocyte predominant Hodgkin?s lymphoma (NLPHL), and primary effusion lymphoma (PEL)), seven T-cell lymphomas (angioimmunoblastic T-cell lymphoma (AILT), anaplastic large-cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATL) hepatosplenic T-cell lymphoma (HSTCL), peripheral T-cell lymphoma not otherwise specified (PTCL or PTCLNOS) as well as cutaneous T-cell lymphomas (CTCL) mycosis fungoides (MF) and Sézary syndrome (SS) and 2 NK/NKT-lymphomas (aggressive natural killer cell lymphoma/leukemia (ANKCL) and extranodal NK-T-cell lymphoma nasal type (ENKTL). Finally, multiple myeloma (MM) is included as its own cancer type.

GSM and GSE refer to GEO identifiers for sample and sample set, respectively. The following data has been collected for each sample when available: additional disease specification, cytogenetic and other relevant alterations, tumor stage, tumor type (e.g. primary, meaning that sample has been taken upon diagnosis before cancer treatment, or relapse), other clinical parameters, patient identifier named in GEO, sample source tissue (e.g. bone marrow), isolation criteria (e.g. mononuclear cells or enrichment based on cell surface marker expression), sample purity/tumor content, patient gender, race, and age as well as marker phenotype of the tumor. Survival and tumor progression status and time to death or relapse is also marked. In addition, treatment information includes treatment type and length for both in vivo and ex vivo treatments. Ex vivo treatments list only treatments that have been done in culture. If the cells have been in cultured in a dish, this has been marked into the separate column Cultured.

HEMAP is an open sourced web application project designed for interactive exploration of cancer maps, annotations and statistical relationships. E-Staining, drug and pathway analysis, remapping and gene expression normalisation guidelines source codes are provided. Software/Usage is free (GNU General Public Licence, v2 no warranty) for non-profit research, please contact Dr. Heinäniemi for raw data.

Matti Nykter, Computational Biology, BioMediTech, University of Tampere
Merja Heinäniemi, Institute of Biomedicin, University of Eastern Finland

We encourage research groups to contribute data for inclusion into the resource; please also contact authors with new feature requests and permissions for commercial usage.
Updated January 19, 2016.